



UNIVERSITY OF LEEDS

This is a repository copy of *Safe and appropriate blood transfusion: mechanism based treatments for anaemia in advanced cancer*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/81308/>

Version: Published Version

---

**Article:**

Neoh, K, Zanker, C and Bennett, M (2013) Safe and appropriate blood transfusion: mechanism based treatments for anaemia in advanced cancer. *BMJ-British Medical Journal*, 347. ARTN f5002. ISSN 1756-1833

<https://doi.org/10.1136/bmj.f5002>

---

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

## LETTERS

## SAFE AND APPROPRIATE BLOOD TRANSFUSION

**Mechanism based treatments for anaemia in advanced cancer**

Karen Neoh *academic clinical fellow in palliative medicine*, Cathy Zanker *honorary researcher*, Mike Bennett *professor of palliative medicine*

Academic Unit of Palliative Care, University of Leeds, Leeds LS2 9LJ, UK

Murphy and colleagues highlight the need to transfuse blood safely and appropriately using a more restrictive approach—transfusing at a lower haemoglobin threshold and using only one unit at a time.<sup>1</sup> This approach is associated with less morbidity and mortality, with similar efficacy. However, the decision whether or not to transfuse needs more attention. In haemodynamically stable patients with chronic anaemia, the benefits of red cell transfusion are far from clear.<sup>2</sup> In part, this probably reflects inadequate assessment and diagnosis of the underlying anaemia.

Anaemia is common in patients with advanced cancer in whom standard management is often red cell transfusion.<sup>3</sup> However, a recent Cochrane review showed that only about half of patients benefit, and the effect lasts only 10–14 days.<sup>4</sup> More worryingly, 23–35% of transfused patients died within 14 days of transfusion, which suggests either inappropriate selection or increased risk of harm from transfusion.

Anaemia in advanced cancer is likely to be caused by functional iron deficiency—hepcidin mediated inhibition of iron metabolism in the presence of systemic inflammation.<sup>5</sup>

Mechanism based treatments for functional iron deficiency can include interleukin antagonists and intravenous iron. These are relatively safe and effective interventions in other chronic diseases, but research is now needed to examine their roles in advanced cancer. Palliative care practice needs to move away from red cell transfusion towards more mechanism based treatments that include more detailed assessment of anaemia.

Competing interests: None declared.

- 1 Murphy MF, Waters JH, Wood EM, Yazer MH. Transfusing blood safely and appropriately. *BMJ* 2013;347:f4303. (16 July.)
- 2 Schrijvers D. Management of anemia in cancer patients: transfusions. *Oncologist* 2011;16:12–8.
- 3 Brown E, Bennett M. Survey of blood transfusion practice for palliative care patients in Yorkshire: implications for clinical care. *J Palliat Med* 2007;10:919–22.
- 4 Preston NJ, Hurlow A, Brine J, Bennett MI. Blood transfusions for anaemia in patients with advanced cancer. Cochrane Pain, Palliative and Supportive Care Group. *Cochrane Database Syst Rev* 2012;2:CD009007.
- 5 Ganz T. Molecular control of iron transport. *J Am Soc Nephrol* 2007;18:394–400.

Cite this as: *BMJ* 2013;347:f5002

© BMJ Publishing Group Ltd 2013